1. Home
  2. SNDX vs LEG Comparison

SNDX vs LEG Comparison

Compare SNDX & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • LEG
  • Stock Information
  • Founded
  • SNDX 2005
  • LEG 1883
  • Country
  • SNDX United States
  • LEG United States
  • Employees
  • SNDX N/A
  • LEG N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • LEG Home Furnishings
  • Sector
  • SNDX Health Care
  • LEG Consumer Discretionary
  • Exchange
  • SNDX Nasdaq
  • LEG Nasdaq
  • Market Cap
  • SNDX 1.3B
  • LEG 1.2B
  • IPO Year
  • SNDX 2016
  • LEG N/A
  • Fundamental
  • Price
  • SNDX $13.51
  • LEG $10.59
  • Analyst Decision
  • SNDX Strong Buy
  • LEG Hold
  • Analyst Count
  • SNDX 11
  • LEG 4
  • Target Price
  • SNDX $38.55
  • LEG $10.50
  • AVG Volume (30 Days)
  • SNDX 3.3M
  • LEG 1.5M
  • Earning Date
  • SNDX 11-03-2025
  • LEG 10-27-2025
  • Dividend Yield
  • SNDX N/A
  • LEG 1.89%
  • EPS Growth
  • SNDX N/A
  • LEG N/A
  • EPS
  • SNDX N/A
  • LEG 1.61
  • Revenue
  • SNDX $77,933,000.00
  • LEG $4,172,899,999.00
  • Revenue This Year
  • SNDX $629.90
  • LEG N/A
  • Revenue Next Year
  • SNDX $114.74
  • LEG N/A
  • P/E Ratio
  • SNDX N/A
  • LEG $6.57
  • Revenue Growth
  • SNDX 2126.66
  • LEG N/A
  • 52 Week Low
  • SNDX $8.58
  • LEG $6.48
  • 52 Week High
  • SNDX $22.50
  • LEG $13.20
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 36.63
  • LEG 74.57
  • Support Level
  • SNDX $13.00
  • LEG $9.07
  • Resistance Level
  • SNDX $15.79
  • LEG $9.39
  • Average True Range (ATR)
  • SNDX 1.10
  • LEG 0.34
  • MACD
  • SNDX -0.26
  • LEG 0.16
  • Stochastic Oscillator
  • SNDX 13.82
  • LEG 94.14

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

Share on Social Networks: